FLT3突变与胶质瘤生存期的新关联:分子遗传学分析
该单中心研究对293例胶质瘤患者的50基因 panel、1p19q共缺失和MGMT启动子甲基化进行检测,采用多变量回归分析总生存期(OS)和无复发生存期(RFS)。结果显示MGMT甲基化和IDH1突变与改善OS和RFS独立相关,而FLT3和TP53突变与更差OS独立相关,FLT3突变与OS的新关联被首次报道。
要点
- MGMT甲基化和IDH1突变与改善OS及RFS独立相关。
- FLT3和TP53突变与更差OS独立相关,FLT3为新型预后标志物。
- 联合分子模型预测价值显著优于仅含临床变量的基础模型。
核心结论
- FLT3突变与胶质瘤患者总生存期(OS)更差存在新关联。
研究设计与样本
- 单中心回顾性队列,纳入293例胶质瘤患者肿瘤组织进行50基因癌症panel、1p19q共缺失和MGMT启动子甲基化检测。
- 构建控制年龄、治疗状态和WHO分级的多变量回归模型分析OS和RFS。
主要发现
- 胶质瘤突变谱随WHO分级显著不同,BRAF V600E、IDH1和PTEN突变分别在高发于WHO I、II/III和IV级肿瘤。
- 多变量分析中,MGMT甲基化(HR=0.44,p=0.0004)和IDH1突变(HR=0.21,p=0.007)与改善OS显著相关。
- FLT3突变(HR=19.46,p<0.0001)和TP53突变(HR=1.67,p=0.014)与更差OS显著相关。
- 仅MGMT甲基化(HR=0.42,p<0.0001)和IDH1突变(HR=0.37,p=0.002)与改善RFS显著相关。
- 联合模型预测价值显著优于基础模型(年龄、手术、放疗、化疗、分级),OS似然比检验p=1.64×10-8,RFS p=3.80×10-7。
临床怎么用
- 胶质瘤分子分型应纳入FLT3突变检测以辅助预后分层。
- MGMT甲基化和IDH1突变可作为预后良好的分子标志物。
- 联合分子标志物与临床变量可提升生存预测准确性。
局限性
- 单中心回顾性研究,结果需外部验证。
- 样本量293例,FLT3突变亚组样本量可能较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recent molecular characterization of gliomas has uncovered somatic gene variation and DNA methylation changes that are associated with etiology, prognosis, and therapeutic response. Here we describe genomic profiling of gliomas assessed for associations between genetic mutations and patient outcomes, including overall survival (OS) and recurrence-free survival (RFS). METHODS: Mutations in a 50-gene cancer panel, 1p19q co-deletion, and MGMT promoter methylation (MGMT methylation) status were obtained from tumor tissue of 293 glioma patients. Multivariable regression models for overall survival (OS) and recurrence-free survival (RFS) were constructed for MGMT methylation, 1p19q co-deletion, and gene mutations controlling for age, treatment status, and WHO grade. RESULTS: Mutational profiles of gliomas significantly differed based on WHO Grade, such as high prevalence of BRAF V600E, IDH1, and PTEN mutations in WHO Grade I, II/III, and IV tumors, respectively. In multivariate regression analysis, MGMT methylation and IDH1 mutations were significantly associated with improved OS (HR = 0.44, p = 0.0004 and HR = 0.21, p = 0.007, respectively), while FLT3 and TP53 mutations were significantly associated with poorer OS (HR = 19.46, p < 0.0001 and HR = 1.67, p = 0.014, respectively). MGMT methylation and IDH1 mutations were the only significant alterations associated with improved RFS in the model (HR = 0.42, p < 0.0001 and HR = 0.37, p = 0.002, respectively). These factors were then included in a combined model, which significantly exceeded the predictive value of the base model alone (age, surgery, radiation, chemo, grade) (likelihood ratio test OS p = 1.64 × 10-8 and RFS p = 3.80 × 10-7). CONCLUSIONS: This study highlights the genomic landscape of gliomas in a single-institution cohort and identifies a novel association between FLT3 mutation and OS in gliomas.
引用
- Shee K, Chambers M, Hughes EG, et al. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. J Neurooncol. 2020. PMID: 32583303. doi:10.1007/s11060-020-03567-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。